← Back to Analyst Consensus 
AVIR Buy
Atea Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Mar 9, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Apr 11, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $6 | 54% |
| Aug 13, 2024 | Morgan Stanley | upgrade | Underweight → Equal-Weight | $6.88 | 54% |
| Aug 10, 2023 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Mar 16, 2023 | JP Morgan | maintain | — → Neutral | $8 | 55% |
| Jan 27, 2023 | SVB Leerink | maintain | — → Market Perform | $6 | — |
| Jan 24, 2023 | Morgan Stanley | maintain | — → Underweight | $4 | 54% |
| Aug 15, 2022 | Morgan Stanley | maintain | — → Underweight | $7 | 54% |
| Mar 2, 2022 | JP Morgan | maintain | — → Neutral | $8 | 55% |
| Mar 1, 2022 | SVB Leerink | maintain | — → Market Perform | $9 | — |
| Feb 16, 2022 | SVB Leerink | maintain | — → Market Perform | $10 | — |
| Jan 6, 2022 | Morgan Stanley | downgrade | Equal-Weight → Underweight | $7 | 54% |
| Nov 18, 2021 | SVB Leerink | downgrade | Outperform → Market Perform | $11 | — |
| Oct 20, 2021 | SVB Leerink | maintain | — → Outperform | $20 | — |
| Oct 20, 2021 | JP Morgan | downgrade | Overweight → Neutral | $16 | 55% |
| Oct 5, 2021 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $55 | 54% |
| Sep 9, 2021 | SVB Leerink | initiate | — → Outperform | $60 | — |
| Aug 18, 2021 | Morgan Stanley | maintain | — → Overweight | $37 | 54% |
| Jun 3, 2021 | Morgan Stanley | maintain | — → Overweight | $35 | 54% |
| Apr 6, 2021 | Morgan Stanley | maintain | — → Overweight | $82 | 54% |
| Jan 29, 2021 | JP Morgan | maintain | — → Overweight | $66 | 55% |
| Nov 25, 2020 | Evercore ISI Group | initiate | — → Outperform | $0 | 58% |
| Nov 24, 2020 | JP Morgan | initiate | — → Overweight | $45 | 55% |
| Nov 24, 2020 | William Blair | initiate | — → Outperform | $0 | 48% |
| Nov 24, 2020 | Morgan Stanley | initiate | — → Overweight | $49 | 54% |
Price Target Trend
Apr 21, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days